Fundraising Fox
🦊/People
Sign in

Kim Kamdar

Investor

General Partner at Domain Partners · Managing Partner at Medical Excellence Capital · Partner at Domain Associates · Board director at Sera Prognostics

San Diego, California, United States

Kauffman Fellow · Class 8

Find your path to Kim

39 people in our graph share verified history with Kim — schools, employers, funds. One of them is your warm intro.

John PrufetaunlockedKim: together at Medical Excellence Capital (2021–2026)
×11Kim: together at Medical Excellence Capital

About

Kim Kamdar, a former Novartis research director and repeat founding CEO (Truvian Sciences, Seraphina Therapeutics), quietly co-founds companies, moves to Chair, and advances global health via Adjuvant Capital.

Contact· self-published, not guessed

Invests in

AI & Machine LearningBiotechHealthtechMedical Devices

Board director at Sera Prognostics

Intro paths

→

In turn, Kim can intro founders to Sera Prognostics's investors below.

Sera Prognostics's investors · 7

aMoonRa'anana · since 2021Catalyst Health VenturesBoston · $1M – $3M checksDomain AssociatesPrinceton · $200K – $15M checksExcelestar VenturesAndoverOUP (Osage University Partners)Bala Cynwyd · $1M – $20M checksUpStart VenturesSalt Lake City · since 2017Vivo CapitalPalo Alto · $10M – $50M checks · since 2021

Experience

  1. Medical Excellence Capital, LLCManaging Partnercurrent2021 — presentSan Diego, California, United States
  2. Domain AssociatesPartnercurrent2005 — present

Deals · 2

Evofem BiosciencesBoard seat

via Domain Associates · filed May 2020 · $25M raise

Tragara PharmaceuticalsBoard seat

via Domain Associates · filed Jul 2015 · $1.2M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Led

Epic SciencesSyndax Pharmaceuticals

Investor

Ariosa DiagnosticsAspen NeuroscienceBiPar SciencesROX MedicalSera PrognosticsSonexa Therapeutics

Sources: curated public sources · SEC Form D filings.

Colleagues at Domain Partners

Annabel Stoddart
Office Manager and Executive Assistant at Medical Excellence Capital
Brad Ringeisen
Scientific Advisory Board – Executive Director of Innovative Genomics Institute at Medical Excellence Capital
Brian Halak
Managing Partner at Medical Excellence Capital
Douglas Wallace
Scientific Advisory Board – Director of Center for Mitochondrial and Epigenomic Medicine at Medical Excellence Capital
Eric Heil
Managing Partner at Medical Excellence Capital
Gregg Semenza
Scientific Advisory Board – Professor at Johns Hopkins at Medical Excellence Capital
Halak Brian
Promoter at Medical Excellence Capital
Heil Eric
Promoter at Medical Excellence Capital

Network4

Charlie PettyMentee
General Partner at Global Health Security
Wouter Meuleman, Ph.D.Mentee
Partner at Illumina Ventures
Brian Dovey
Partner at Domain Associates
Dennis Podlesak
Venture Partner at Domain Associates

Investors connected to Kim in public investor directories — a warm-intro map.

Frequently asked questions

Who is Kim Kamdar?
Kim Kamdar, a former Novartis research director and repeat founding CEO (Truvian Sciences, Seraphina Therapeutics), quietly co-founds companies, moves to Chair, and advances global health via Adjuvant Capital.
Where does Kim Kamdar work?
Kim Kamdar is General Partner at Domain Partners and Board director at Sera Prognostics.
What does Kim Kamdar invest in?
Kim Kamdar invests in AI & Machine Learning, Biotech, Healthtech, Medical Devices.
What boards does Kim Kamdar sit on?
Kim Kamdar holds tracked board seats at Evofem Biosciences, Tragara Pharmaceuticals.
What companies has Kim Kamdar invested in?
Investments tracked here include Epic Sciences, Syndax Pharmaceuticals, Ariosa Diagnostics, Aspen Neuroscience, BiPar Sciences, Evofem Biosciences, ROX Medical, Sera Prognostics, Sonexa Therapeutics.
Does Kim Kamdar lead rounds?
Yes — Kim Kamdar has led 2 tracked investments.